LC
EWTX icon

Lindbrook Capital’s Edgewise Therapeutics EWTX Stock Holding History

Lindbrook Capital’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$6.27K Sell
285
-40
-12% -$1.05K ﹤0.01% 1863
2024
Q4 		$8.68K Hold
325
– – ﹤0.01% 1722
2024
Q3 		$8.67K Buy
325
+28
+9% +$557 ﹤0.01% 1752
2024
Q2 		$5.35K Buy
297
+83
+39% +$1.45K ﹤0.01% 1961
2024
Q1 		$3.9K Hold
214
– – ﹤0.01% 2006
2023
Q4 		$2.34K Buy
+214
New +$1.5K ﹤0.01% 2210
2023
Q3 		– Sell
-154
Closed -$1.19K – 2726
2023
Q2 		$1.19K Sell
154
-369
-71% -$3.11K ﹤0.01% 2332
2023
Q1 		$3.49K Buy
523
+362
+225% +$3.35K ﹤0.01% 2013
2022
Q4 		$1.44K Buy
161
+25
+18% +$234 ﹤0.01% 2372
2022
Q3 		$1K Buy
+136
New +$1.37K ﹤0.01% 2312

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Lindbrook Capital's EWTX Position: Q1 2025 in Review

Lindbrook Capital reduced its Edgewise Therapeutics (EWTX) stake by 12% in Q1 2025, selling an estimated $1.05K and leaving 285 shares worth $6.27K. The position accounts for ﹤0.01% of the portfolio, ranked #1863.

Lindbrook Capital first reported a position in EWTX in Q3 2022 and has held it in 10 quarters since. The position peaked at $8.68K in Q4 2024. 192 funds tracked by Wall St. Rank hold EWTX as of Q1 2025.

  • Lindbrook Capital held 285 shares of Edgewise Therapeutics worth $6.27K as of Q1 2025.
  • Lindbrook Capital sold 40 Edgewise Therapeutics shares in Q1 2025, an estimated $1.05K.
  • Edgewise Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1863 holding.
  • Lindbrook Capital first reported a position in Edgewise Therapeutics in Q3 2022 and has held it in 10 quarters since.
  • Lindbrook Capital's Edgewise Therapeutics position peaked at $8.68K in Q4 2024.
  • 192 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.